Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Phase 2
Withdrawn
- Conditions
- Lymphoma
- Interventions
- Other: Oral Cryotherapy (ice chips)Biological: Stem Cell Infusion
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
Phase 1
Recruiting
- Conditions
- CardiomyopathyHeart FailureHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- Other: Best PracticeOther: Laboratory Biomarker AnalysisDrug: Mesenchymal Stem Cell Transplantation
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT02962661
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1
Completed
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAplastic AnemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoblastic LymphomaMyelodysplastic SyndromeMyeloproliferative Neoplasm
- Interventions
- Biological: FilgrastimOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationBiological: RituximabRadiation: Total-Body Irradiation
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02960646
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Phase 1
Active, not recruiting
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Other: Laboratory Biomarker AnalysisRadiation: Palliative Radiation TherapyRadiation: Radiation Therapy
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02959463
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
Phase 2
Active, not recruiting
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT02960555
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit
Not Applicable
Completed
- Conditions
- Malignant Neoplasms of Independent (Primary) Multiple SitesAdvanced Cancer
- Interventions
- Behavioral: Baseline QuestionnairesOther: VideosBehavioral: Assessment Questionnaires
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 121
- Registration Number
- NCT02957565
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Recurrent Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT02953561
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
Phase 2
Terminated
- Conditions
- Malignant Neoplasms of Mesothelial and Soft TissueGastrointestinal Stromal Tumor With Neurogenic Differentiation
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02949947
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Withdrawn
- Conditions
- Lung Cancer, Nonsmall Cell, Stage I
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02950038
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2
Withdrawn
- Conditions
- Recurrent Primary Peritoneal CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- Biological: Anti-CSF1 Monoclonal Antibody PD-0360324Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02948101
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath